Table 5.

Characteristics of patients with ABPA receiving omalizumab with and without AR.

	All participants	With AR	Without AR	P
Baseline Data
Blood eosinophil count, cells/µL	590 (270–840)	510 (190–910)	630 (580–930)	0.40
Total serum IgE level, kU/L	2627 ± 1904	2540 ± 2050	2846 ± 1736	1.00
Dose of corticosteroids, mg/d	2.5 (0.6–12)	2.5 (0.6–14)	4.5 (0.6–11)	0.89
ACT score	17 ± 5	16 ± 6	18 ± 4	0.67
FVC %pre	81 ± 13	80 ± 11	83 ± 15	0.48
FEV1%pre	69 ± 15	68 ± 15	71 ± 15	0.78
Acute exacerbation rate	2 (0.8–3.3)	1.5 (0.8–3.0)	3.5 (0.5–5.0)	0.32
Hospitalization rate	1 (0–1.3)	0.5 (0–1.0)	1.5 (0.3–4.3)	0.20
After treatment
Blood eosinophil count, cells/µL	180 (120–490)	240 (110–600)	106 (110–420)	0.62
Total serum IgE level, kU/L	1913 ± 1898	2384 ± 2040	737 ± 735	0.16
Dose of corticosteroids, mg/d	0.6 (0.5–4.2)	0 (0.5–4.2)	0.8 (0.1–6.3)	0.94
ACT score	22 ± 3	21 ± 3	23 ± 1	0.67
FVC %pre	86 ± 17	84 ± 15	89 ± 22	0.40
FEV1%pre	76 ± 18	77 ± 18	74 ± 21	0.67
Acute exacerbation rate	0 (0–1.0)	0 (0–1.3)	0 (0–0.8)	0.51
Hospitalization rate	0 (0–0)	0 (0–0.3)	0 (0–0)	0.35

ABPA, allergic bronchopulmonary aspergillosis; AR, allergic rhinitis; ACT, asthma control test;

FEV1, percentage of the forced expiratory volume in 1 s; FEV1%pre, forced expiratory volume in 1 s of predicted